Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Shwachman-Bodian-Diamond syndrome (SBDS) protein is a direct inhibitor of protein phosphatase 2A (PP2A) activity and overexpressed in acute myeloid leukaemia.
Dun MD, Mannan A, Rigby CJ, Butler S, Toop HD, Beck D, Connerty P, Sillar J, Kahl RGS, Duchatel RJ, Germon Z, Faulkner S, Chi M, Skerrett-Byrne D, Murray HC, Flanagan H, Almazi JG, Hondermarck H, Nixon B, De Iuliis G, Chamberlain J, Alvaro F, de Bock CE, Morris JC, Enjeti AK, Verrills NM. Dun MD, et al. Among authors: kahl rgs. Leukemia. 2020 Dec;34(12):3393-3397. doi: 10.1038/s41375-020-0814-0. Epub 2020 Apr 8. Leukemia. 2020. PMID: 32269318 Free PMC article. No abstract available.
Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors.
Smith AM, Dun MD, Lee EM, Harrison C, Kahl R, Flanagan H, Panicker N, Mashkani B, Don AS, Morris J, Toop H, Lock RB, Powell JA, Thomas D, Guthridge MA, Moore A, Ashman LK, Skelding KA, Enjeti A, Verrills NM. Smith AM, et al. Oncotarget. 2016 Jul 26;7(30):47465-47478. doi: 10.18632/oncotarget.10167. Oncotarget. 2016. PMID: 27329844 Free PMC article.
Functional importance of PP2A regulatory subunit loss in breast cancer.
Watt LF, Panicker N, Mannan A, Copeland B, Kahl RGS, Dun MD, Young B, Roselli S, Verrills NM. Watt LF, et al. Among authors: kahl rgs. Breast Cancer Res Treat. 2017 Nov;166(1):117-131. doi: 10.1007/s10549-017-4403-5. Epub 2017 Jul 25. Breast Cancer Res Treat. 2017. PMID: 28744751
Quantitative phosphoproteomics uncovers synergy between DNA-PK and FLT3 inhibitors in acute myeloid leukaemia.
Murray HC, Enjeti AK, Kahl RGS, Flanagan HM, Sillar J, Skerrett-Byrne DA, Al Mazi JG, Au GG, de Bock CE, Evans K, Smith ND, Anderson A, Nixon B, Lock RB, Larsen MR, Verrills NM, Dun MD. Murray HC, et al. Among authors: kahl rgs. Leukemia. 2021 Jun;35(6):1782-1787. doi: 10.1038/s41375-020-01050-y. Epub 2020 Oct 16. Leukemia. 2021. PMID: 33067575 Free PMC article. No abstract available.
Phospho-heavy-labeled-spiketide FAIMS stepped-CV DDA (pHASED) provides real-time phosphoproteomics data to aid in cancer drug selection.
Staudt DE, Murray HC, Skerrett-Byrne DA, Smith ND, Jamaluddin MFB, Kahl RGS, Duchatel RJ, Germon ZP, McLachlan T, Jackson ER, Findlay IJ, Kearney PS, Mannan A, McEwen HP, Douglas AM, Nixon B, Verrills NM, Dun MD. Staudt DE, et al. Among authors: kahl rgs. Clin Proteomics. 2022 Dec 19;19(1):48. doi: 10.1186/s12014-022-09385-7. Clin Proteomics. 2022. PMID: 36536316 Free PMC article.
Correction to: Phospho-heavy-labeled-spiketide FAIMS stepped-CV DDA (pHASED) provides real-time phosphoproteomics data to aid in cancer drug selection.
Staudt DE, Murray HC, Skerrett-Byrne DA, Smith ND, Jamaluddin MFB, Kahl RGS, Duchatel RJ, Germon ZP, McLachlan T, Jackson ER, Findlay IJ, Kearney PS, Mannan A, McEwen HP, Douglas AM, Nixon B, Verrills NM, Dun MD. Staudt DE, et al. Among authors: kahl rgs. Clin Proteomics. 2023 Apr 8;20(1):16. doi: 10.1186/s12014-023-09406-z. Clin Proteomics. 2023. PMID: 37031204 Free PMC article. No abstract available.
19 results